Article Text

PDF
Growth hormone and respiratory compromise in Prader–Willi Syndrome
  1. S S I Wilson1,
  2. A M Cotterill2,
  3. M-A Harris1
  1. 1Department of Respiratory and Sleep Medicine, Mater Children’s Hospital, South Brisbane, Australia
  2. 2Department of Endocrinology, Mater Children’s Hospital, South Brisbane, Australia
  1. Correspondence to:
    Dr M-A Harris
    Department of Respiratory and Sleep Medicine, Mater Children’s Hospital, Raymond Terrace, South Brisbane QLD 4101, Australia; margaret.harris{at}mater.org.au

Abstract

Recombinant human growth hormone (rhGH) therapy in Prader–Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.

  • growth hormone
  • Prader-Willi syndrome
  • sleep apnoea syndrome
  • respiratory insufficiency
  • basal metabolism

Statistics from Altmetric.com

Footnotes

  • Competing interests: none declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.